Articles by Murray Aitken - Pharmaceutical Executive


Articles by Murray Aitken

Back Page: Withdrawal Syndrome

In the wake of Vioxx, the public wants safer drugs. But tougher standards need to come with new tools for managing risk, or innovation will stall. That's the adverse event no-one's talking about.
Dec 1, 2004

There's nothing like a product withdrawal to put the pharmaceutical industry under the microscope. Following Merck's decision to withdraw Vioxx from the market, a flurry of reports in the US media suggested a need to re-examine and overhaul everything from the drug approval process, to direct-to-consumer advertising, to the way pharma handles R&D. Our challenge as an industry is to use the Vioxx case as a catalyst for making thoughtful improvements to our current practices—improvements that build on the many things we are doing right.


Click here